Gilead Sciences, Inc.‘s (NASDAQ:GILD) inventory worth has fallen 4% over the previous two months, which I estimate is especially on account of continued apathy and concern on Wall Road even after progress in tariff negotiations between the U.S. and India and an finish to Trump’s assaults on Federal Reserve Chairman Jerome Powell.
On the identical time, on Could 23, it revealed the outcomes of the Part 3 ASCENT-03 medical trial through which taking Trodelvy [sacituzumab govitecan] led to a statistically vital enchancment in a medical metric known as progression-free survival in sufferers with metastatic TNBC who weren’t eligible for PD-1/PD-L1 inhibitors [a class of immunotherapy medications that includes Keytruda and Tecentriq] in contrast with these within the chemotherapy group.
I consider that this achievement by Gilead, along with the promising knowledge from the ASCENT-04 trial, will result in the label expansions for Trodelvy.
In the end, it would contribute to raised demand for this TROP2-directed ADC, which has declined barely within the final two quarters, partially on account of intensified competitors from AstraZeneca PLC’s (AZN) Enhertu.
So, its gross sales amounted to $293 million within the first three months of 2025, down 5.2% year-on-year.
Ought to Gilead Sciences traders be nervous about its prospects in 2025 and past?
If I run just a little forward and communicate briefly, then I consider that no.
Do I proceed to cowl Gilead Sciences with a ‘Purchase’ ranking?
First, I wish to level out that to reply this query as objectively as doable, I not solely analyzed the efficiency of Gilead Sciences’ key medicines but in addition its current achievements because the publication of my article “Why Gilead Sciences Stays A Purchase After A 40% Rally.”
Given this, in addition to the completion of the technical correction in its share worth, I proceed to consider that Gilead Sciences is a inventory with robust long-term progress
